KFDA to approve clinical studies for 12 gene recombinant products.

Published: 2005-12-21 06:59:00

Updated: 2005-12-21 06:59:00

The KFDA approved the clinical studies for 12 gene recombinant drugs including LB03002, a sustained type of human growth hormone developed by LG Life Science, Tifacogin inj. (Quintiles Korea), Remicade inj. 100mg (Infliximab mono clonal antibody by Schering Plough), Aropoetine free filled inj. (human erythropoietine by Daehan Jedang), ISU301 (absiximab mono clonal antiboty by Isuepzis, LS...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.